But now, Abbott’s FreeStyle Libre 2 and 3 have received the first and only FDA clearance that allows patients to keep their ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Abbott announced today that the FDA said users can wear the FreeStyle Libre 2 and 3 CGMs during common imaging procedures.

Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

A major development towards the goal of patient and provider choice, the cloud-to-cloud integration will provide an automatic ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

IRVINE, CA / ACCESSWIRE / October 30, 2024 / Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes ...

FreeStyle Libre continues to gain market share and driving the diabetes sales growth for Abbott. Abbott maintains its total 2024 revenue guidance of 9.5% to 10% growth on an organic basis.

Oct 16 (Reuters) - Abbott Laboratories (ABT.N), opens new tab slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as Abbott's popular FreeStyle Libre. The company's ...